FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

A / a a la i a a 4 a a	D C	20540
Vashington,	D.C.	20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours ner resnons	e· 0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* O'Neill Julie				HO	Issuer Name and Ticker or Trading Symbol HOOKIPA Pharma Inc. [HOOK] Date of Earliest Transaction (Month/Day/Year)							(Ch	eck all appli X Directo	or		son(s) to Iss 10% Ow Other (s	ner	
(Last)	(Fi	irst)	(Middle)			06/09/2023								below)	(give title		below)	pecily
C/O HOOKIPA PHARMA INC. 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240					4. If <i>F</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	Individual or Joint/Group Filing (Check Applicable le) X Form filed by One Reporting Person				
(Street) NEW Y	ORK N	Y	10118										Form filed by More than One Reporting Person					
(City)	(Si	tate)	(Zip)			Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contrasatisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction								on or writter	ı plan t	hat is intende	d to	
		Tab	le I - Noi	n-Deriv	ative	Sec	curities	s Ac	quired, D	isp	osed o	of, or Be	neficial	ly Owne	d			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da					Execution Date,		Code (Ins	Transaction Disposed Of Code (Instr. 5)		ities Acquired (A) or d Of (D) (Instr. 3, 4 and		Benefici	es ally following	Form (D) o	Form: Direct of (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	V	Amount	ount (A) or (D)		Transac (Instr. 3	ction(s)				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	Date,	4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	lly	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code V (A) (D) Exercisable Expiration					Title	Amount or Number of Shares							
Stock Option (Right to Buy)	\$1.01	06/09/2023			A		26,000		(1)	06.	/09/2033	Common Stock	26,000	\$0	26,000)	D	

Explanation of Responses:

1. This option shall vest and become fully exercisable on the earlier to occur of (a) June 9, 2024 and (b) the date of the Issuer's 2024 annual meeting of its stockholders.

/s/ Reinhard Kandera, as

06/09/2023

Attorney-in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.